Treats active duodenal ulcer. ANDA 203203, held by Xiromed. Lansoprazole.
As of Nov 21, 2026, ANDA 203203 (Lansoprazole), held by Xiromed, was first approved by FDA on Jul 25, 2016, with 7 approved supplements and 0 published complete response letters.
Lansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults Maintenance of healed duodenal ulcers in adults Treatment of active benign gastric ulcer in adults Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults Risk reduction of NSAID-associated gastric ulcer in adults Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 25, 2016 | Original application | Approved | None posted |
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Lansoprazole30MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Apr 6, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 6, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 6, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 20, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 20, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 20, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 20, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 25, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters